<DOC>
	<DOC>NCT01614886</DOC>
	<brief_summary>To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.</brief_summary>
	<brief_title>Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>A diagnosis of dementia of the Alzheimer's type according to the DSMIV criteria A clinical diagnosis of probable AD according to NINCDS/ADRDA criteria An MMSE score of ≥ 10 and ≤ 20 at baseline Any medical or neurological conditions other than AD that could explain the patient's dementia A current diagnosis of probable or possible vascular dementia A score of &gt; 5 on the Modified Hachinski Ischemic Scale (MHIS) A current DSMIV Axis 1 diagnosis that may interfere with the evaluation of the patient's response to study medication. Treated with donepezil or galantamine within last 4 weeks before the efficacy assessment at baseline. an advanced severe progressive or unstable disease of any type that may interfere with efficacy and safety assessments or put the patient's at special risk Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Rivastigmine, Alzheimer's disease, Transdermal patch</keyword>
</DOC>